Background: Resuscitation guided by thrombelastography improves survival after injury. If bleeding is rapid, however, or if no thrombelastography data are available, the optimal strategy remains controversial. Our current practice gives fresh frozen plasma and red blood cells (1:2) empirically in patients with lifethreatening hemorrhage, with subsequent administration based on rapid thrombelastography. We identified patients at risk of massive transfusion at 1 hour, examined their initial rapid thrombelastography, and used this value to provide empiric recommendations about transfusions. Methods: Massive transfusion was defined as > 4 units of red blood cells in the first hour. Patients managed by a trauma activation (2014-2017) had an admission rapid thrombelastography analyzed to determine what proportion met thresholds for administration of cryoprecipitate or platelets. Results: Overall, 35 patients received > 4 units of red blood cells in the first hour. Based on the admission rapid thrombelastography, 37% met criteria for both platelets and cryoprecipitate, 35% for either platelets or cryoprecipitate and 29% for neither. Kaplan-Meier analysis showed a significant delay in the administration of cryoprecipitate and platelets compared to fresh frozen plasma. Conclusion: Patients who require > 4 units of red blood cells within the first hour should receive cryoprecipitate and platelets if thrombelastography results are not available. Point-of-care devices are needed for optimal care of trauma-induced-coagulopathy, but these data offer guidance in their absence.
Introduction
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with increased mortality, and methods to treat this disorder effectively are needed. 4 In patients requiring massive transfusion, resuscitation guided by rapid thrombelastography (rTEG) results in decreased mortality with a decrease in administration of blood products compared to conventional clotting assays or ratio-based strategies. 5, 6 This approach resulted in our current institutional protocol of 1:2 fresh frozen plasma (FFP):red blood cell (RBC) transfusion in patients in hemorrhagic shock, with simultaneous blood collection for rTEG to guide need for additional blood product use. 7, 8 There are certain scenarios, however, where rapid hemorrhage outpaces TEG results, and we are left with a dilemma of which products should be given to the bleeding patient.
To provide guidance for this group of patients, we needed to identify patients who require a massive transfusion (MTx) at an early time point. Traditional MTx definitions use RBC units over a span of time (from 6 to 24 hours) to identify patients at greatest risk of death. 7, 9 Ideally, we would identify patients at greatest risk of death in a more rapid time frame, preferably within the first hour. Additionally, while traditional definitions provide a single cut point to identify patients at greatest risk of death, these traditional definitions do not identify populations at low and intermediate risk. 10 Initially, we sought to stratify patients into low, intermediate, and high risk for death based on RBC units transfused within the first 1 to 24 hours. We then hypothesized that if we identified patients at greatest risk of death within 1 hour of admission, we could identify a dominant coagulopathy in this group, and from that, provide empiric recommendations for transfusion.
Methods

Study design
This is an analysis of prospectively collected data from critically injured trauma patients. Inclusion criteria were patients ≥18 years of age that met the highest-level trauma activation at Denver Health Medical Center, an urban level 1 trauma center. Exclusion criteria were unsalvageable injuries (death ≤30 minutes from time of injury), prolonged transit time ( ≥1 hour), isolated gunshot wounds to the head, pregnancy, and a documented coagulation disorder (including liver disease). All studies were approved by the Colorado Multiple Institutional Review Board (COMIRB) under a waiver of consent.
Clinical data and rapid thrombelastography
Clinical data were abstracted by trained profession research assistants (PRAs). Data on RBC units transfused 1, 2, 4, 6, 12, and 24 hours from injury were collected. PRAs collected blood in citrated vacuum tubes at the time of admission. Blood samples were analyzed using the rTEG assay (exogenous addition of tissue factor and kaolin) on the TEG 50 0 0 Thrombelastography Hemostasis Analyzer (Haemonetics, Niles, IL, USA), as described previously. 11 The following indices were obtained from the tracings of the TEG: activated clotting time (ACT, in seconds), angle ( °), maximum amplitude (MA [mm]), and lysis 30 min after MA (LY30 [%]). Threshold for fresh FFP (ACT > 128 seconds), cryoprecipitate (Cryo) (angle < 65 °) and platelet (Plt) (MA < 55 mm) administration were based on prior investigations. 8 Administration of blood products was in accordance with these thresholds by treating physicians using the clinical lab rTEG. 8 Physicians were blinded to the research rTEG values.
Massive transfusion definition
Receiver operating characteristic (ROC) curves to predict death based on RBC units transfused (within 1, 2, 4, 6, 12, and 24 hours of injury) were constructed. Area under the ROC curve (AUROC) of ≥0.7 was the cutoff for a good predictor of death. Interval likelihood ratios are defined as the slope of the ROC curve between any two points on the ROC curve (point A and B), 12 calculated as (Sensitivity of Point A -Sensitivity of Point B)/(Specificity of Point B -Specificity of Point A). The positive likelihood ratio ( + LHR) in this setting modifies the pretest probability of death, a + LHR > 1 increased the post-test probability of death, with a greater + LHR increasing the post-test probability. 10 We used the + LHR to stratify patients into groups. MTx was defined as the least number of RBC units that corresponded to a + LHR for death of > 10x, the high risk group. 10 An intermediate zone was defined as a + LHR for death of 5x (or as close to 5x as could be obtained). The low risk group was the cohort receiving less RBC units than the intermediate risk group. ROC curves were analyzed with and without exclusion of patients with severe TBI (traumatic brain injury) (head AIS (abbreviated injury score) > 3) to avoid confounders from death due to traumatic brain injury.
Indicated blood products and time to administration
Patients who received an MTx in the first hour were stratified by their admission rTEG into groups based on the dominant coagulopathy present-a shallow angle indicating the need for Cryo, a low MA indicating the need for Plt, or both. Those without an admission rTEG were excluded from this analysis. Our institutional practice is to give 1:2 FFP:RBC; these patients all receive empiric FFP, and therefore, we did not assess the need for FFP transfusion. 8 We performed the same analysis on the intermediate and the low risk groups (after exclusion of patients who received no blood products in the first hour) and compared the incidence of any coagulopathy between groups. Subsequently, we sought to identify if our transfusion practices result in a delayed administration of Plt and Cryo compared to FFP in our current protocols. Patients who underwent an MTx within 1 hour ( > 4 units of RBC in the first hour, head AIS ≤3) and had admission coagulopathy underwent Kaplan Meier curve analysis to time to first unit of blood products transfused (FFP, Cryo, or Plt).
Statistical analysis
Non-normally distributed variables were expressed as median and interquartile range (IQR) and the Wilcoxon nonparametric test was used for comparisons. Mantel-Cox test was used to compare survival curves. All tests were two-tailed with significance declared at P < .05.
Results
Patient characteristics
In this study, 626 patients met criteria and were analyzed ( Table 1 ). There were 86 deaths in this cohort (13.7% aggregate mortality). The cause of death was due to a traumatic brain injury (TBI) in 55% of patients, hemorrhage in 38% (due to either uncontrolled bleeding or physiologic collapse secondary to massive hemorrhage), organ failure in 5%, and other causes in the remaining 2% of patients. Of patients who died within the first day, 72% died within the first 6 hours, and overall, 63% of deaths occurred within 24 hours from presentation and 80% within 3 days from admission.
Ability of RBC transfusions to predict death
ROC curves were calculated for the ability of RBC transfusions to predict death ( Fig 1 ) . The AUROC was 0.71 for RBC units in the first hour indicating that this was a reasonably good predictor of death; however, when patients with severe TBI were excluded from this group, the performance increased with an AUROC for death of 0.83 ( Table 2 ) . Performance of RBC units to predict death increased at 2 hours from injury; however, RBC units at later time points did not improve prediction compared to 2 hours. Due to the fact that excluding patients with severe TBI improved the performance of RBC units to predict death, we calculated the intermediate risk and MTx ranges after excluding this group ( Table 3 ) . Massive transfusion was defined as > 4 units in 1 hour, > 6 units in 2 hours, > 8 units in hours, > 10 units in 6 hours, and > 12 hours in 12 or 24 hours. The intermediate risk for death was defined as 4 units of RBC in the first hour or 9-10 units in the first 6 hours ( Table 3 ) .
Indicated blood products
Using the above definitions, we identified those patients who received > 4 units of RBC in the first hour from injury are at high risk of death. We performed an analysis of this group of patients ( n = 35) to determine the coagulation abnormalities present on admission rTEG to determine if there existed a dominant coagulopathy in this group ( Fig 2 , C ) . Of these patients, 6% of patients had a coagulopathy requiring Cryo only, 29% had a coagulopathy requiring Plt only, 37% had a coagulopathy requiring both Cryo and Plt, and only 29% had no admission coagulopathy ( Fig 2 ) . Empiric treatment with Plt required treating 1.5 patients with platelets to appropriately target 1 patient; for Cryo 2.3 patients would be treated to appropriately target 1 patient. When compared to the low and intermediate risk groups, there was a difference in the presence of any coagulopathy (as assessed by Angle or MA, P < .0 0 01), with an increase in coagulopathy from the low to intermediate to MTx groups ( P < .0 0 01, χ 2 test for trend). In the low and intermediate risk groups, 80% and 48% of patients had no products indicated, respectively.
Time to product administration
Kaplan-Meier analysis ( Fig. 3 ) revealed delayed administration of Plt and Cryo compared to FFP, median time to administration of FFP was within 1 hour, within 2 hours for Plt and Cryo. Greater than 75% of patients who had Plt or Cryo as indicated by the admission rTEG received these products within 4 hours. Of those patients who did not receive Plt or Cryo within 6 hours, 62% of these patients died within 2 hours from injury.
Discussion
In this study, we have identified thresholds to differentiate patients at high, intermediate, and low risk of death based on RBC units transfused at different time intervals. These thresholds provide us the ability to identify patients at greatest risk of death within the first hour of admission. Analysis of this population revealed that the most common coagulopathy present on admission required treatment with Plt and Cryoprecipitate. Additionally, we showed that under current transfusion protocols, these patients have substantially delayed administration of both Cryo and Plt compared to FFP. Based on this observation, we recommend in this population empiric transfusion of both Plt and Cryo in patients who require > 4 units of RBC within the first hour from admission if the rTEG data are not available.
The historic definition of MTx (10 units of RBC in 24 hours) is widely acknowledged to have limitations. 9 , 13-15 Chief among these limitations is that this definition of MTx misses patients who may die before receiving 10 units; does not include a measure of acuity of hemorrhage; and only carries value as a retrospective metric and not at the point-of-care. We first suggested this time interval be shortened to 6 hours, but the majority of post-injury deaths due to exsanguination occur within 2 hours in an MTx population. 7, 16 Our updated definition allows for rapid identification of MTx patients during the first hour after injury. Additionally, the inclusion of TBI into the decision decreases the ability to predict death, particularly at early time points, because hemorrhage is not a predominant cause of death in that population. In this study, 55% of patients died secondary to head injury and substantially less died as a sequelae of hemorrhage. Compared to prior work attempting to identify MTx at more rapid time points, which used ≥3 units in any hour period, we reported a greater threshold at 1 hour ( > 4 units of RBC), but at 2 hours, we have a similar threshold ( > 6 units). 17 Importantly we show that after 2 hours, the ability of RBC units transfused to predict death plateaus and that using a 6-to 24-hour window may not be necessary.
Outside of the ability to predict MTx at rapid time points, these novel definitions offer an additional nuance that is missed in traditional MTx definitions. By stratifying the non-MTx group into an intermediate risk of MTx and low risk of MTx, we can identify an additional endpoint for prospective trials. Although an intervention may not decrease the rate of MTx, it may transition an intermediate risk patient into a low risk patient and improve clinical outcomes. Furthermore, when power is an issue for clinical trials due to the low rate of death or MTx, by adding another outcome, we can add patients to increase power and improve the ability of a smaller study to detect small differences.
Although many groups advocate fixed-ratio resuscitation, they have not been able to show an improved mortality with this approach. 18, 19 In contrast, TEG-based resuscitation results in improved mortality compared to conventional clotting assays or fixed ratio protocols. 5, 6 Our study does not aim to supplant the TEGdriven protocols currently in use and replace them with fixed-ratio strategies but rather fill a knowledge gap in a small subset of patients. In the scenario where the bleeding is rapid and transfusion needs outpace TEG results, we suggest empiric transfusion of both platelets and cryoprecipitate with continued 1:2 FFP:RBC. By using the threshold of > 4 units in the first hour, we have identified populations with a high risk of death, but also those patients that are likely to outpace the rapidity of TEG based resuscitation. These data suggest that empiric treatment with Plt will benefit more patients than empiric treatment with Cryo; however, when weighing the risks of under-treatment compared to over-treatment of coagulopathy, we would favor over-treatment in this group. After 4 units of RBC and 2 of FFP, we have begun to resuscitate the patient from shock and provide an optimal environment for Cyro and Plt to counteract any coagulopathy. Extrapolation of empiric, ratiobased transfusion policies to all bleeding patients would result in unnecessary administration of blood products, because 80% of patients who receive 1-3 units of RBC in the first hour have no indication for either Cryo or Plt. We cannot say with certainty why there are delays in the administration of Cryo and Plt compared to FFP, although contributions due to waiting for the TEG results and intentional design of the MTx cooler composition (Cryo and Plt are only present in the second cooler brought to a trauma activation to allow resuscitation from shock) are likely responsible. We would expect Cryo and Plt, however, only to be delayed until the TEG results-which, regardless of rate of bleeding, is quicker than the 2 hours median for Plt and Cryo transfusion. We aim to address both of these issues by suggesting empiric transfusion if more than 4 units of RBC have been administered. Given that the majority of patients who did not receive the indicated Plt or Cryo within 6 hours died within the first 2 hours, we anticipate that by moving toward more rapid transfusion, we may be able to improve survival.
The retrospective nature of this study is a limitation, while the small sample size does not allow analysis of whether more rapid administration of Plt and Cryo will improve incidence of ongoing coagulopathy and survival in this cohort. Prospective analysis is needed to ensure that the suggested changes result in improved survival, although retrospective studies suggest a survival benefit of early Plt transfusion. 20 There is a risk that administration of products to the small cohort of patients who do manifest a coagulopathy will worsen outcomes (particularly with regard to late organ injury), although recent studies have shown that increased blood product administration is not a risk for ARDS (acute respiratory distress syndrome). 21 This study provides a threshold for MTx of > 4 units in the first hour, which is a simple assessment to make in the heat of the moment and requires no lab results or calculation to determine. In this group, although empiric transfusion of both Cryo and Plt is reasonable based on the dominant patterns of coagulopathy observed, our study highlights the need for more rapid point-of-care assessment of coagulopathy to allow individualized correction of coagulopathy. Furthermore, these data suggest that trauma centers review both transfusion policies and practice, because such a review may reveal delays in care and opportunities for quality improvement.
